Reclast Receives US Approval As A Highly Effective Treatment For Patients With Paget's Disease Of The Bone (Medical News Today)
Reclast (zoledronic acid) has received US regulatory approval as the first new treatment in nearly a decade for patients with a bone condition known as Paget's disease, estimated to affect about one million people in the US alone[1]. [click link for full article]

Banner year for biotech drugs (Pharmalicencing)
The FDA outdid itself last year, granting first-time approvals to 43 new biotech-derived medicines and 36 supplemental indications for drugs and biologics developed by specialty and big pharma companies as well as biotech firms.